Spinraza in Adult Spinal Muscular Atrophy

Active, not recruitingOBSERVATIONAL
Enrollment

148

Participants

Timeline

Start Date

August 16, 2018

Primary Completion Date

December 31, 2024

Study Completion Date

January 1, 2025

Conditions
Spinal Muscular AtrophySpinal Muscular Atrophy Type IISpinal Muscular Atrophy Type 3
Interventions
DRUG

Observational study to examine safety, tolerability, and effectiveness of SPINRAZA® prescribed as part of standard of care

This is an observational study of adult patients with SMA to examine the safety, tolerability, and effectiveness of SPINRAZA® (nusinersen) for up to 30 months.

OTHER

One time survey

One time survey

Trial Locations (11)

10003

New York University School of Medicine, New York

20007

Georgetown University, Washington D.C.

21287

Johns Hopkins, Baltimore

23507

Children's Hospital of the King's Daughthers, Norfolk

48867

Memorial Healthcare, Owosso

63110

Washington University School of Medicine, St Louis

77030

Houston Methodist Neurological Institute, Houston

85013

Barrow Neurological Institute, Phoenix

98195

University of Washington, Seattle

02114

Massachusetts General Hospital-Harvard University, Boston

H3A 2B4

Montreal Neurological Institute and Hospital, Montreal

All Listed Sponsors
lead

Washington University School of Medicine

OTHER

NCT03709784 - Spinraza in Adult Spinal Muscular Atrophy | Biotech Hunter | Biotech Hunter